Denali Therapeutics (DNLI) Revenue (2018 - 2023)
Historic Revenue for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to $1.3 million.
- Denali Therapeutics' Revenue fell 6440.01% to $1.3 million in Q3 2023 from the same period last year, while for Jun 2024 it was $1.3 million, marking a year-over-year decrease of 9963.07%. This contributed to the annual value of $330.5 million for FY2023, which is 20474.08% up from last year.
- Per Denali Therapeutics' latest filing, its Revenue stood at $1.3 million for Q3 2023, which was down 6440.01% from $294.1 million recorded in Q2 2023.
- In the past 5 years, Denali Therapeutics' Revenue ranged from a high of $316.8 million in Q4 2020 and a low of $1.3 million during Q3 2023
- Moreover, its 5-year median value for Revenue was $9.4 million (2020), whereas its average is $44.3 million.
- Its Revenue has fluctuated over the past 5 years, first tumbled by 9628.25% in 2019, then skyrocketed by 668114.3% in 2020.
- Denali Therapeutics' Revenue (Quarter) stood at $4.7 million in 2019, then surged by 6681.14% to $316.8 million in 2020, then plummeted by 96.05% to $12.5 million in 2021, then decreased by 17.83% to $10.3 million in 2022, then tumbled by 87.68% to $1.3 million in 2023.
- Its Revenue was $1.3 million in Q3 2023, compared to $294.1 million in Q2 2023 and $35.1 million in Q1 2023.